CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies.

[1]  L. Schwartzberg,et al.  An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. , 1995, Blood.

[2]  R. Jacobs,et al.  Combined transplantation of allogeneic bone marrow and CD34+ blood cells. , 1995, Blood.

[3]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Gordon My,et al.  Some factors determining the minimum number of cells required for successful clinical engraftment. , 1995 .

[5]  H. Heimpel,et al.  In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. , 1995, Bone marrow transplantation.

[6]  F. Benvenuto,et al.  Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation. , 1995, Bone marrow transplantation.

[7]  L. Terstappen,et al.  Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. , 1995, Blood.

[8]  R. Storb,et al.  Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantation , 1994, British journal of haematology.

[9]  A. Winkelstein,et al.  Enumeration of CD34+ hematopoietic stem cells for reconstitution following myeloablative therapy. , 1994, Cytometry.

[10]  M. Cottler-Fox,et al.  Quality assurance in flow cytometry: comparison of three analytical methods for quantifying CD34+ cells in marrow. , 1994, Progress in clinical and biological research.

[11]  G. Reaman,et al.  Extended-cycle elutriation to adjust T-cell content in HLA-disparate bone marrow transplantation. , 1993, Blood.

[12]  M. Baccarani,et al.  The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications. , 1992, Haematologica.

[13]  B. Glass,et al.  Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. , 1992, Blood.

[14]  R. Miller,et al.  Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow transplant recipients. , 1987, Blood.

[15]  H. Heimpel,et al.  Hemopoietic reconstitution after bone marrow transplantation. , 1986, Experimental hematology.

[16]  J. Biggs,et al.  Lack of correlation between nucleated bone marrow cell dose, marrow CFU‐GM dose or marrow CFU‐E dose and the rate of HLA‐identical sibling marrow engraftment , 1985, British journal of haematology.

[17]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[18]  T. Makinodan,et al.  Mortality of mice as affected by variation of the x-ray dose and number of nucleated rat bone marrow cells injected. , 1957, Cancer research.